Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.
You may also be interested in...
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.
US big pharma manufacturers generally delivered sales and earnings growth in the second quarter and reaffirmed guidance despite currency headwinds; US drug pricing legislation could present a tipping pressure point.
Congressional Democrats achieved a long-sought goal in passing major legislation to control drug prices in Medicare. A complete lack of Republican support suggests the programs established by the bill will face the same kind of legislative and legal challenges that confronted the Affordable Care Act, which was enacted in a similar manner.